Presenter: Alyson Ridpath, DO PGY-3
Dermatology Program: OhioHealth O’Bleness
Program Director: Dawn Sammons, DO, FAOCD
Submitted on: Feb 21, 2018
CHIEF COMPLAINT: A 67-year-old male with stage IV BRAF- and c-Kit-negative, NRAS-positive melanoma of unknown primary with metastases to the liver, lung and brain was started on nivolumab 3 mg/kg every two weeks.
CLINICAL HISTORY:
Signs and symptoms: After 16 cycles over 32 weeks, he presented to the emergency department with a new, severe, pruritic, bullous eruption covering approximately 90% body surface area, and altered mental status
Continue reading “Generalized blisters after nivolumab treatment”